急性淋巴细胞白血病大剂量甲氨蝶呤化疗中护肝药物应用的必要性研究  被引量:2

Clinical studies of the necessity of application of lump drugs of high-dose methotrexate on liver in children with acute lymphoblastic leukemia

在线阅读下载全文

作  者:黄闪[1] 刘炜[1] 

机构地区:[1]郑州市儿童医院血液肿瘤科,河南郑州450000

出  处:《医药前沿》2016年第21期46-48,共3页Journal of Frontiers of Medicine

摘  要:目的:研究急性淋巴细胞白血病大剂量甲氨蝶呤化疗中护肝药物应用的必要性。方法:收集本院2012年1月~2015年1月4年间156例在本院给予大剂量甲氨蝶呤化疗患儿化疗期间ALT、AST、ALP、TBA、TBil等肝酶的变化,按化疗初即给予护肝药物和不给予护肝药物分为两组,研究两组患儿化疗后转氨酶的转归。结果:两组患儿化疗后ALT、AST、ALP、TBA、TBil等肝酶的变化无明显统计学差异(P〉0.05)。结论:急性淋巴细胞白血病大剂量甲氨蝶呤化疗期间给予护肝药物治疗不能明显降低化疗药物肝损害程度,因此大剂量甲氨蝶呤化疗可不常规给予护肝药物治疗。Objective To study the necessity of application of lump drugs of high-dose methotrexate on liver in children with acute lymphoblastic leukemia.Methods From Jan 2012 to Jan 2015,156 hospitalized children with acute lymphoblastic leumia were enrolled in the study and divided into two groups: protect liver of the beginning of the chemotherapy(76 cases) and no protect liver of the beginning of the chemotherapy( 80 cases), tio study the viriation of the function of liver between the pre and post chemotherapy.Results There were no ststistical differences between the levels of ALT、AST、ALP、γ-GT in both groups at post chemotherapy.Conclusion Acute lymphocytic leukemia during high-dose methotrexate chemothrexate chemotherapy to protect liver medicine not significantly reduce chemothereapy drugs liver damage degree, so the high-dose mrthotreate chemotherapy is not normal to protect liver medicine.

关 键 词:甲氨蝶呤 急性淋巴细胞白血病 儿童 肝功能 

分 类 号:R575[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象